DocDollars

Genmab U.S., Inc.

NJ · United States · Reporting entity ID 100000956830

Total reported 2019–2025
$54.6M
#162 of 2,960 reporting companies — 0.1% of all reported industry payments
$4.82M in general payments across 21,571 records, plus $49.3M in research funding across 3,617 records.

How it breaks down

General payments $4,816,660
Research funding $49,257,336
Ownership & investment $486,019

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Genmab U.S., Inc. reported $54.6M to US doctors and teaching hospitals from 2019 to 2025, ranking #162 of 2,960 reporting companies. 90% of that was research funding and 10% general payments such as consulting, speaking, food and travel. 21,571 general payment records and 3,617 research records were filed.

Common questions about Genmab U.S., Inc.

How much has Genmab U.S., Inc. paid US doctors?

Genmab U.S., Inc. reported $54,560,014 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $4,816,660 in general payments, $49,257,336 in research funding and $486,019 in ownership and investment interests.

How does Genmab U.S., Inc. rank among drug and device companies?

It ranks #162 of 2,960 reporting entities by total reported value, about 0.1% of all industry payments in the dataset.

Does a payment from Genmab U.S., Inc. mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.